||FUNCTION: Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. ENZYME REGULATION: Inhibited by N-ethylmaleimide. SUBCELLULAR LOCATION: Cytoplasm (Probable).? SIMILARITY: Belongs to the peptidase C54 family.
||See product label
||A synthetic peptide (CTVYNSDVIDKQ) corresponding to the C-terminal of human ATG4C protein conjugated to Blue Carrier Protein has been used as the immunogen. The peptide is homologous with the corresponding sequence derived from ATG4C protein in mouse and rat.
||Cysteine protease ATG4C; Autophagy-related protein 4 homolog C; Autophagin-3; Autophagy-related cysteine endopeptidase 3; AUT-like 3 cysteine endopeptidase; ATG4C; APG4C; AUTL3;
|| ATG4 C_HUMAN
||IHC, immunofluorescence and WB. A dilution of 1:100 to 1:2000 dilution is recommended for these applications. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
||IHC, ELISA and WB confirmed the specificity for ATG4C.
||Human, rat. Other species not yet tested.
||Reconstitute in 100 uL of sterile water. Centrifuge to remove any insoluble material.
||After reconstitution keep aliquots at -20C for a higher stability, and at 2-8C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
||Six months after purchase
||Smuder AJ et al. (2011) Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle.
J Appl Physiol (1985). 2011 Oct;111(4):1190-8.
||1. Marino G, et al. J. Biol. Chem. 278:3671-3678(2003).
2. Ota T, et al. Nat. Genet. 36:40-45(2004).